Company
Dexcom
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
29
510(k), De Novo and PMA
Device trials
28
As lead sponsor, any status
Adverse event reports
331,569
Received Nov 1, 2025 to Nov 19, 2026
Recall records
29
One per recalled product
Dexcom is on our public-company list (ticker DXCM). Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements, plus private placements it reported on Form D.
Listed
DXCM
Nasdaq · DEXCOM INC
Public float
$34.2B
Value of shares held by non-insiders on Jun 30, 2025
Revenue
$4.66B
Fiscal year ending Dec 31, 2025
Net income
$836M
Fiscal year ending Dec 31, 2025
R&D spending
$599M
Fiscal year ending Dec 31, 2025
Cash
$961M
As of Sep 30, 2026
Long-term debt
$1.24B
As of Sep 30, 2026
Shares outstanding
373.0M
As of Oct 22, 2026
Capital raised as a public company
Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.
| Year | IPO | Stock sold | Long-term debt | Convertible debt |
|---|---|---|---|---|
| 2025 | – | $28.1M | – | – |
| 2024 | – | $28.2M | – | – |
| 2023 | – | $26.6M | – | $1.23B |
| 2022 | – | $22.5M | – | – |
| 2021 | – | $20.3M | – | – |
Private placements (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| May 2, 2016 | Equity Issued in a merger or acquisition; not counted as money raised | $7.2M | $7.2M | 2 | Rule 506(b) | Form D ↗May 18, 2016 |
Company details
From the company's latest Form D.
- Legal name
- DEXCOM INC
- Headquarters
- San Diego, California
- Incorporated
- Delaware over five years before filing
- Entity type
- Corporation
- Revenue range
- Decline to Disclose
- Industry filed under
- Biotechnology
- SEC filer
- CIK 1093557 ↗
Executives, directors and promoters
As listed on the latest Form D.
- Richard DoubledayExecutive Officer
- Eric TopolDirector
- Barbara KahnDirector
- Steven PacelliExecutive Officer
- Jonathan LordDirector
- Jeffrey MoyExecutive Officer
- Nicholas AugustinosDirector
- Terrance GreggExecutive Officer, Director
- Jorge ValdesExecutive Officer
- John ListerExecutive Officer
- Jess RoperExecutive Officer
- Andrew BaloExecutive Officer
- Jay SkylerDirector
- Kevin SayerExecutive Officer, Director
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
The investor database is part of the paid tier
It is included for signed-in readers who have credit, along with the daily news digest. Credit is also what pays for AI device summaries.
Latest FDA decisions
The 8 newest of 29 since 2015.
K262472 · Decided Aug 11, 2026 · 25 days after receipt
Device type: Integrated Continuous Glucose Monitor For Non-Intensive Glucose Management, Over-The-Counter (SBH) · Laboratory Medicine & Pathology
K260935 · Decided Jun 12, 2026 · 84 days after receipt
Device type: Integrated Continuous Glucose Monitor For Non-Intensive Glucose Management, Over-The-Counter (SBH) · Laboratory Medicine & Pathology
- Dexcom G7 Continuous Glucose Monitoring System;Dexcom G7 15 Day Continuous Glucose Monitoring System510(k)
K261402 · Decided Jun 8, 2026 · 40 days after receipt
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ) · Laboratory Medicine & Pathology
K261359 · Decided May 21, 2026 · 27 days after receipt
Device type: Integrated Continuous Glucose Monitor For Non-Intensive Glucose Monitoring, Over-The-Counter (SAF) · Laboratory Medicine & Pathology
K253737 · Decided Feb 3, 2026 · 71 days after receipt
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ) · Laboratory Medicine & Pathology
K253710 · Decided Dec 17, 2025 · 23 days after receipt
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ) · Laboratory Medicine & Pathology
- Dexcom Smart Basal510(k)
K252818 · Decided Nov 18, 2025 · 75 days after receipt
Device type: Continuous Glucose Monitor Informed Insulin Dose Calculator (QRX) · Laboratory Medicine & Pathology
K243214 · Decided Apr 9, 2025 · 188 days after receipt
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ) · Laboratory Medicine & Pathology
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry (Dexcom Global Registry)Active, not recruiting
NCT06483945 · 5,000 participants (planned) · Start Feb 28, 2024 · Primary completion Mar 31, 2028
Device: Dexcom CGM G6/G6 Pro/G7 · For: Diabetes
Sites: Stockbridge, Georgia; Las Vegas, Nevada
- CONtiNuous glucosE Monitoring (CGM) in People wiTh Type 2 Diabetes Not on InsulinPivotal-lookingActive, not recruiting
NCT06601166 · 283 participants · Start Aug 15, 2024 · Primary completion May 13, 2026
Device: CGM · For: Type 2 Diabetes
Sites: Aurora, Colorado; Denver, Colorado; Lake City, Florida · 21 sites in all
- Evaluation of Basal Insulin Initialization and Titration in People With Type 2 Diabetes Wearing a Dexcom G6 SensorActive, not recruiting
NCT07681375 · 45 participants · Start Apr 11, 2023 · Primary completion Jan 16, 2026
Device: Dexcom Continuous Glucose Monitoring (CGM) · For: Type 2 Diabetes
Sites: San Diego, California
- Global Long-term Outcomes and Real-World Evaluation of Dexcom Continuous Glucose Monitoring System (Dexcom GLOW)Not yet recruiting
NCT07681024 · 5,000 participants (planned) · Start Jun 15, 2026 · Primary completion May 1, 2030
Device: Dexcom CGM (Continuous Glucose Monitor) · For: Diabetes
- Continuous Glucose Monitoring By DExcom iN PEople Followed for Type 2 DIabeTes on Insulin Therapy in the Kingdom of Saudi ArabiaActive, not recruiting
NCT07603284 · 200 participants (planned) · Start Nov 24, 2025 · Primary completion Nov 2, 2026
Device: Real-Time Continuous Glucose Monitoring · For: Type 2 Diabetes on Insulin
Sites: Riyadh, Saudi Arabia
NCT05746286 · 40 participants · Start Feb 1, 2023 · Primary completion Nov 29, 2023
Device: Dexcom G6 CGM · For: Dysglycemia
Sites: New York, New York
Reports received
331,569
Received Nov 1, 2025 to Nov 19, 2026. Includes 211 of another or unstated type.
Malfunction reports
323,697
98% of reports
Injury reports
7,607
2.3% of reports
Death reports
54
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 23,256 | 297 | 0 | 1 |
| Jan 24 | 27,360 | 433 | 1 | 0 |
| Feb 24 | 23,201 | 348 | 1 | 0 |
| Mar 24 | 22,543 | 341 | 2 | 0 |
| Apr 24 | 26,324 | 358 | 1 | 0 |
| May 24 | 28,044 | 402 | 2 | 0 |
| Jun 24 | 24,706 | 556 | 5 | 0 |
| Jul 24 | 33,523 | 466 | 1 | 1 |
| Aug 24 | 32,058 | 398 | 1 | 2 |
| Sep 24 | 30,037 | 462 | 4 | 1 |
| Oct 24 | 31,830 | 409 | 2 | 1 |
| Nov 24 | 29,170 | 356 | 1 | 1 |
| Dec 24 | 26,910 | 423 | 3 | 3 |
| Jan 25 | 27,717 | 489 | 3 | 0 |
| Feb 25 | 20,964 | 511 | 3 | 0 |
| Mar 25 | 25,723 | 467 | 0 | 0 |
| Apr 25 | 27,450 | 471 | 1 | 0 |
| May 25 | 31,372 | 588 | 0 | 3 |
| Jun 25 | 31,970 | 611 | 1 | 1 |
| Jul 25 | 37,747 | 736 | 3 | 4 |
| Aug 25 | 35,163 | 754 | 5 | 2 |
| Sep 25 | 32,826 | 699 | 3 | 6 |
| Oct 25 | 32,128 | 683 | 4 | 1 |
| Nov 25 | 21,500 | 560 | 6 | 0 |
| Dec 25 | 22,108 | 648 | 3 | 0 |
| Jan 26 | 77,742 | 582 | 4 | 1 |
| Feb 26 | 19,559 | 483 | 6 | 0 |
| Mar 26 | 21,981 | 618 | 5 | 0 |
| Apr 26 | 18,655 | 597 | 3 | 0 |
| May 26 | 18,012 | 630 | 4 | 0 |
| Jun 26 | 23,131 | 626 | 8 | 0 |
| Jul 26 | 26,725 | 715 | 6 | 40 |
| Aug 26 | 26,740 | 677 | 5 | 79 |
| Sep 26 | 23,475 | 824 | 0 | 52 |
| Oct 26 | 24,069 | 647 | 4 | 39 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
- DEXCOM G7387
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2574-2026 · Started May 27, 2026 · Posted by FDA Jun 24, 2026
Reason given: Certain lots of Dexcom G7 sensors originally designated as scrap and intended for destruction were stolen during the destruction process. The sensors were later sold to pharmacies and distributors by Pharmsource, LLC. Lot 1725204004 were designated for destruction because the G7 sensors were not properly sterilized...
Cause as FDA categorized it: Nonconforming Material/Component · Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
Z-2163-2026 · Started Apr 14, 2026 · Posted by FDA May 11, 2026
Reason given: A software defect in which a low-priority file I/O check blocks the higher-priority thread responsible for processing estimated glucose values (EGVs) and trend arrows. When the app is running in the background, EGV notifications may queue up and then "replay" sequentially when the user brings the app to the...
Cause as FDA categorized it: Software design · Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
Z-2164-2026 · Started Apr 14, 2026 · Posted by FDA May 11, 2026
Reason given: A software defect in which a low-priority file I/O check blocks the higher-priority thread responsible for processing estimated glucose values (EGVs) and trend arrows. When the app is running in the background, EGV notifications may queue up and then "replay" sequentially when the user brings the app to the...
Cause as FDA categorized it: Software design · Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
Z-2165-2026 · Started Apr 14, 2026 · Posted by FDA May 11, 2026
Reason given: A software defect in which a low-priority file I/O check blocks the higher-priority thread responsible for processing estimated glucose values (EGVs) and trend arrows. When the app is running in the background, EGV notifications may queue up and then "replay" sequentially when the user brings the app to the...
Cause as FDA categorized it: Software design · Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
Z-0318-2026 · Started Aug 28, 2025 · Posted by FDA Oct 30, 2025
Reason given: A software defect in version v1.15.0 of the G6 Android app can cause the app to terminate unexpectedly, which may result in the user not receiving estimated glucose values, alarms, alerts or notifications. This could result in the missed detection of a hyperglycemic or hypoglycemic event, protentional resulting in...
Cause as FDA categorized it: Software Design Change · Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
Z-2446-2025 · Started Jul 24, 2025 · Posted by FDA Sep 4, 2025
Reason given: The affected devices are the Dexcom G7 Continuous Glucose Monitoring System (CGM System) using iOS, watchOS and Android App software (versions 2.8.0 or earlier) and Dexcom ONE+ CGM System using iOS and Android App software (versions 1.4.0 or earlier), henceforth referred to as the App. The affected App does not...
Cause as FDA categorized it: Software design · Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
Z-2447-2025 · Started Jul 24, 2025 · Posted by FDA Sep 4, 2025
Reason given: The affected devices are the Dexcom G7 Continuous Glucose Monitoring System (CGM System) using iOS, watchOS and Android App software (versions 2.8.0 or earlier) and Dexcom ONE+ CGM System using iOS and Android App software (versions 1.4.0 or earlier), henceforth referred to as the App. The affected App does not...
Cause as FDA categorized it: Software design · Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
Z-2448-2025 · Started Jul 24, 2025 · Posted by FDA Sep 4, 2025
Reason given: The affected devices are the Dexcom G7 Continuous Glucose Monitoring System (CGM System) using iOS, watchOS and Android App software (versions 2.8.0 or earlier) and Dexcom ONE+ CGM System using iOS and Android App software (versions 1.4.0 or earlier), henceforth referred to as the App. The affected App does not...
Cause as FDA categorized it: Software design · Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
Showing the 8 newest of 29 recall records in FDA's data.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.